How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?-Reference-Cited by-同舟云学术

How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?

Published:2024-03-23 Issue:5 Volume:25 Page:571-584
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Lozupone Madia¹^ORCID,Dibello Vittorio²³^ORCID,Daniele Antonio⁴⁵,Solfrizzi Vincenzo²,Resta Emanuela⁶,Panza Francesco²^ORCID

Affiliation:

1. Department of Translational Biomedicine and Neuroscience “DiBraiN”, University of Bari Aldo Moro, Bari, Italy

2. Department of Interdisciplinary Medicine, “Cesare Frugoni” Internal and Geriatric Medicine and Memory Unit, University of Bari Aldo Moro, Bari, Italy

3. Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

4. Department of Neuroscience, Catholic University of Sacred Heart, Rome, Italy

5. Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy

6. Translational Medicine and Health System Management, Department of Economy, University of Foggia, Foggia, Italy

Funder

Development of an ensemble learning-based, multi-dimensional sensory impairment score to predict cognitive impairment in an elderly cohort of Southern Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2345734

Reference54 articles.

1. Tau pathology and neurodegeneration

2. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau

3. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

4. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

5. Progressive Supranuclear Palsy